Trial | NCT02388035  Report issue

Official Title

Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    cefotaxime ...

  • Study Participants

    254
Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.
Study Started
Mar 31
2015
Primary Completion
May 31
2015
Study Completion
Jun 30
2015
Last Update
Jun 04
2015
Estimate

Drug Cefotaxime

SBP-group 1 Experimental

Spontanous bacterial peritonitis

CNNA-group 2 Experimental

Culture negative neutrocytic ascites

MNBA-group 3 Experimental

monomicrobial non-neutrocytic ascites

group 4 No Intervention

no evidence of ascitic fluid infection

Criteria 

Inclusion Criteria:

patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection

Exclusion Criteria:

Patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases
No Results Posted